313 related articles for article (PubMed ID: 32316408)
21. Network-based co-expression analysis for exploring the potential diagnostic biomarkers of metastatic melanoma.
Wang LX; Li Y; Chen GZ
PLoS One; 2018; 13(1):e0190447. PubMed ID: 29377892
[TBL] [Abstract][Full Text] [Related]
22. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
23. Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis.
Yang L; Xu Y; Yan Y; Luo P; Chen S; Zheng B; Yan W; Chen Y; Wang C
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31557882
[TBL] [Abstract][Full Text] [Related]
24. Exploration and validation of the effects of robust co-expressed immune-related genes on immune infiltration patterns and prognosis in laryngeal cancer.
Zeng H; Huang Y; Chen L; Li H; Ma X
Int Immunopharmacol; 2020 Aug; 85():106622. PubMed ID: 32485354
[TBL] [Abstract][Full Text] [Related]
25. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
26. Coexpressed Genes That Promote the Infiltration of M2 Macrophages in Melanoma Can Evaluate the Prognosis and Immunotherapy Outcome.
Yan K; Wang Y; Lu Y; Yan Z
J Immunol Res; 2021; 2021():6664791. PubMed ID: 33748290
[TBL] [Abstract][Full Text] [Related]
27. Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.
Qu Y; Zhang S; Zhang Y; Feng X; Wang F
Virchows Arch; 2021 May; 478(5):943-959. PubMed ID: 33179141
[TBL] [Abstract][Full Text] [Related]
28. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
29. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H
Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043
[TBL] [Abstract][Full Text] [Related]
30. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
31. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
32. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.
Lim SY; Lee JH; Gide TN; Menzies AM; Guminski A; Carlino MS; Breen EJ; Yang JYH; Ghazanfar S; Kefford RF; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2019 Mar; 25(5):1557-1563. PubMed ID: 30409824
[TBL] [Abstract][Full Text] [Related]
33. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
35. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
36. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Prognostic 3-Gene Risk Prediction Model for Thyroid Cancer.
Zhao H; Zhang S; Shao S; Fang H
Front Endocrinol (Lausanne); 2020; 11():510. PubMed ID: 32849296
[No Abstract] [Full Text] [Related]
38. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
[TBL] [Abstract][Full Text] [Related]
39. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
[TBL] [Abstract][Full Text] [Related]
40. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
